140 related articles for article (PubMed ID: 8395825)
1. The Epstein-Barr virus DNA polymerase transactivates the human immunodeficiency virus type 1 5' long terminal repeat.
Lin JC
Biochem Biophys Res Commun; 1993 Aug; 195(1):242-9. PubMed ID: 8395825
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1.
Scala G; Quinto I; Ruocco MR; Mallardo M; Ambrosino C; Squitieri B; Tassone P; Venuta S
J Virol; 1993 May; 67(5):2853-61. PubMed ID: 8386279
[TBL] [Abstract][Full Text] [Related]
3. Regulation of NF-kappaB and HIV-1 LTR activity in mouse L cells by ultraviolet radiation: LTR trans-activation in a nonirradiated genome in heterokaryons.
Miller SC; Taylor A; Watanabe K; Mok K; Torti FM
Exp Cell Res; 1997 Jan; 230(1):9-21. PubMed ID: 9013701
[TBL] [Abstract][Full Text] [Related]
4. Gene activation mediated by protein kinase C in human macrophage and teratocarcinoma cells expressing aminoglycoside phosphotransferase activity.
Maio JJ; Brown FL
J Cell Physiol; 1991 Dec; 149(3):548-59. PubMed ID: 1660486
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of the basal-level activity of HIV-1 long terminal repeat by HIV-1 nucleocapsid protein.
Zhang JL; Sharma PL; Crumpacker CS
Virology; 2000 Mar; 268(2):251-63. PubMed ID: 10704334
[TBL] [Abstract][Full Text] [Related]
6. Retinoblastoma gene inhibits transactivation of HIV-LTR linked gene expression upon co-transfection in He La cells.
Prasad MV; Shanmugam G
Biochem Mol Biol Int; 1993 Jan; 29(1):57-62. PubMed ID: 8490568
[TBL] [Abstract][Full Text] [Related]
7. Transactivation of human immunodeficiency virus by herpesviruses.
Rando RF; Pellett PE; Luciw PA; Bohan CA; Srinivasan A
Oncogene; 1987 Mar; 1(1):13-8. PubMed ID: 2830574
[TBL] [Abstract][Full Text] [Related]
8. Human immunodeficiency virus type 1 vpr protein transactivation function: mechanism and identification of domains involved.
Forget J; Yao XJ; Mercier J; Cohen EA
J Mol Biol; 1998 Dec; 284(4):915-23. PubMed ID: 9837715
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of relative promoter strengths of the HIV-1-LTR and a chimeric RSV-LTR in T lymphocytic cells and peripheral blood mononuclear cells: promoters for anti-HIV-1 gene therapies.
Mukhtar M; Duan L; Bagasra O; Pomerantz RJ
Gene Ther; 1996 Aug; 3(8):725-30. PubMed ID: 8854098
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 Nef protein inhibits the recruitment of AP-1 DNA-binding activity in human T-cells.
Niederman TM; Hastings WR; Luria S; Bandres JC; Ratner L
Virology; 1993 May; 194(1):338-44. PubMed ID: 8480425
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the HIV-1 LTR NF-kappaB-proximal Sp site III: evidence for cell type-specific gene regulation and viral replication.
McAllister JJ; Phillips D; Millhouse S; Conner J; Hogan T; Ross HL; Wigdahl B
Virology; 2000 Sep; 274(2):262-77. PubMed ID: 10964770
[TBL] [Abstract][Full Text] [Related]
12. Activation of the human immunodeficiency virus type I long terminal repeat by 1 alpha,25-dihydroxyvitamin D3.
Nevado J; Tenbaum SP; Castillo AI; Sánchez-Pacheco A; Aranda A
J Mol Endocrinol; 2007 Jun; 38(6):587-601. PubMed ID: 17556530
[TBL] [Abstract][Full Text] [Related]
13. Modulation of HIV-LTR activity by ras oncogenes.
Lembo D; Angeretti A; Gaboli M; Cavallo R; Landolfo S
New Microbiol; 1995 Apr; 18(2):111-6. PubMed ID: 7603337
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional activation of the human immunodeficiency virus long terminal repeat sequences by tumor necrosis factor.
Zoumpourlis V; Eliopoulos AG; Spandidos DA
Anticancer Res; 1992; 12(6B):2065-8. PubMed ID: 1295450
[TBL] [Abstract][Full Text] [Related]
15. Identification of human cytomegalovirus target sequences in the human immunodeficiency virus long terminal repeat. Potential role of IE2-86 binding to sequences between -120 and -20 in promoter transactivation.
Yurochko AD; Huong SM; Huang ES
J Hum Virol; 1999; 2(2):81-90. PubMed ID: 10225210
[TBL] [Abstract][Full Text] [Related]
16. Role of glucocorticoid receptor binding sites in the human immunodeficiency virus type 1 long terminal repeat in steroid-mediated suppression of HIV gene expression.
Mitra D; Sikder SK; Laurence J
Virology; 1995 Dec; 214(2):512-21. PubMed ID: 8553553
[TBL] [Abstract][Full Text] [Related]
17. P32/TAP, a cellular protein that interacts with EBNA-1 of Epstein-Barr virus.
Wang Y; Finan JE; Middeldorp JM; Hayward SD
Virology; 1997 Sep; 236(1):18-29. PubMed ID: 9299613
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine.
Jiang MC; Lin JK; Chen SS
Biochem Biophys Res Commun; 1996 Sep; 226(1):1-7. PubMed ID: 8806583
[TBL] [Abstract][Full Text] [Related]
19. Response of human immunodeficiency virus long terminal repeat to growth factors and hormones.
Spandidos DA; Zoumpourlis V; Kotsinas A; Tsiriyotis C; Sekeris CE
Anticancer Res; 1990; 10(5A):1241-5. PubMed ID: 2241099
[TBL] [Abstract][Full Text] [Related]
20. Transactivation of methylated HIV-LTR by a frog virus 3 protein.
Spangler CM; Essani K
Virology; 1994 Nov; 204(2):651-5. PubMed ID: 7941333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
